AstraZeneca to Implement $35 Cap on Inhaler Prices Starting June 1

Monday, 18 March 2024, 15:36

AstraZeneca has announced a groundbreaking decision to limit out-of-pocket costs for its inhaler products to $35 per month, effective June 1. This move, following similar actions by competitor Boehringer Ingelheim, aims to address concerns over high inhaler prices and anticompetitive practices, as well as demands for healthcare reform by lawmakers such as Sen. Bernie Sanders. The company's decision comes amidst growing scrutiny and criticism over the pricing discrepancy between inhalers in the U.S. and other countries.

https://store.livarava.com/7bdffd5c-e53d-11ee-967d-5254a2021b2b.jpe — AstraZeneca to Implement $35 Cap on Inhaler Prices Starting June 1

AstraZeneca Caps Inhaler Prices at $35

Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, effective June 1. The cap will apply to the range of inhalers used to treat asthma and COPD, including Symbicort, Breztri Aerosphere and Airsupra.

Anticompetitive Practices Under Scrutiny

The move by AstraZeneca follows actions by Boehringer Ingelheim amid concerns over high inhaler prices and potential delays in generic products entering the market.

Call for Healthcare Reform

Lawmakers, led by Sen. Bernie Sanders, are investigating major inhaler manufacturers for pricing disparities between the U.S. and other countries. AstraZeneca's decision is seen as a step towards addressing affordability issues in healthcare.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

AstraZeneca Caps Inhaler Prices at $35

Anticompetitive Practices Under Scrutiny

Call for Healthcare Reform

Related posts